Form D · Pharmaceuticals
Pneuma Respiratory, Inc.
Boone, NC · CIK 0001701794
Offering snapshot reported Jul 1, 2026 · SEC filing
- Reported sold
- $3.57M Indefinite offering
- Investors reported
- 19 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 18, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 1, 2026 | Initial | $3,570,115 | No comparison | 19 | SEC filing |
| Dec 3, 2025 | Amendment | $3,304,000 | $0vs Jun 23, 2025 | 14 | SEC filing |
| Dec 3, 2025 | Amendment | $2,996,000 | $0vs May 14, 2025 | 26 | SEC filing |
| Jun 23, 2025 | Initial | $3,304,000 | No comparison | 14 | SEC filing |
| May 14, 2025 | Amendment | $2,996,000 | $0vs May 13, 2025 | 25 | SEC filing |
| May 13, 2025 | Initial | $2,996,000 | No comparison | 25 | SEC filing |
| Dec 23, 2024 | Initial | $7,340,000 | No comparison | 68 | SEC filing |
| Aug 10, 2021 | Amendment | $6,898,219 | No comparison | Not reported | SEC filing |
| Feb 18, 2021 | Initial | $429,585 | No comparison | 18 | SEC filing |
| Feb 18, 2021 | Initial | $437,794 | No comparison | 4 | SEC filing |
| Feb 17, 2021 | Amendment | $5,055,793 | $64,260vs Feb 21, 2020 | 20 | SEC filing |
| Feb 21, 2020 | Amendment | $4,991,533 | $4,691,531vs Jul 30, 2019 | 19 | SEC filing |
| Jul 30, 2019 | Initial | $300,002 | No comparison | 3 | SEC filing |
| Jul 30, 2019 | Amendment | $4,999,906 | $158,703vs May 17, 2019 | 34 | SEC filing |
| May 17, 2019 | Amendment | $4,841,203 | $49,928vs May 6, 2019 | 33 | SEC filing |
| May 6, 2019 | Amendment | $4,791,275 | $208,632vs Apr 18, 2019 | 32 | SEC filing |
| Apr 18, 2019 | Amendment | $4,582,643 | $1,784,738vs Apr 5, 2019 | 29 | SEC filing |
| Apr 5, 2019 | Amendment | $2,797,905 | $2,303,782vs Mar 12, 2019 | 15 | SEC filing |
| Mar 12, 2019 | Initial | $494,123 | No comparison | 4 | SEC filing |
| May 31, 2018 | Amendment | $8,106,688 | $2,122,418vs Mar 23, 2018 | 52 | SEC filing |
| Mar 23, 2018 | Initial | $5,984,270 | No comparison | 38 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0 (estimated)
- Finders' fees
- $0 (estimated)
- Form D file number
- 021-589327
Common Stock and Warrants to Purchase Common Stock
Source: Form D, filed Jul 1, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Richard A. Gimigliano | Executive |
| Farnkh Hameed | Director |
| Farrukh Hameed | Director |
| John Hand | Director |
| C. Eric Hunter | Director, Executive |
| Jocelyn Hunter | Executive |
| J. Knox Morgan | Director |
| Jay Phillip Morgan | Director |
| Walter L. Robb | Director |
| May Shen | Executive |
| J. Knox Singleton | Director |
| Douglas E. Singleton | Director |
| Douglas E. Stoner | Director |
| Sally Yanchus | Executive |
| Wei Zheng | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
870 State Farm Road, Suite 103 B
Boone, NC, 28607
Phone: (828) 772-2602
Boone, NC, 28607
Phone: (828) 772-2602